An organ-on-a-chip is a multi-channel 3-D microfluidic cell culture chip which pretends the mechanics, activities and physiological response of entire organ systems and organ, a type of artificial organ. Not only has this, constructing valid artificial organs needs not only a detailed cellular manipulation but a precise understanding of the human body’s fundamental involved response to any event. The scientific advances in cell biology, microfluidics and microfabrication have led to the improvement of Organ-on-chips (OOCs). Whereas, the OOCs are micro fluidic 3D cell culture devices which strictly imitate the important physiological functions of the body organs. Developments in the Testing Of Human Organs-On-Chips, Organ-On-Chip Technology In Space, Automated Monitoring Of Organs-On-Chips, 3D Printing Of Organs-On Chips, Manufacturers Tying Up With End-Users To Design Tailor-made Products, Investment In Integration Of Individual Organs-on-Chips Into Humans-on-Chips, Strong Focus On Development of Custom Organs-On-Chips, and Manufacturers Work On Disease Models To Expedite Drug Testing are the major trends in the market of organ-on-chip across the globe by which the market has grown in the recent trend in an auspicious manner.
According to the report analysis, ‘Organ-On-Chip Global Market Opportunities And Strategies To 2021 Including: Lung-On-Chip, Heart-On-Chip, Liver-On-Chip, Intestine-On-Chip, Kidney-On-Chip, Skin-On-Chip, Blood-Brain-Barrier-On-Chip And Human-On-Chip Covering: CN Bio Innovations,Emulate, TissUse, Mimetas, Hurel, Nortis, InSphero,Tara Biosystems, AxoSim Technologies, Organovo, Ascendence And HemoShear’ states that some of the major companies which are currently functioning in this sector more actively for attaining the highest growth in the global market of organ-on-chip by defeating the increasing demand of potential consumers involve Emulate Inc., HREL Corporation (HREL), Nortis, Tara Bio systems, AxoSimTechologies LLC, Organovo, ASCENDANCE BIOTECHNOLOGY – HEPREGEN,CN Bio Innovations, TissUse GmbH, Mimetas, InSphero, HemoShear, Roche Holding AG, Elvesys, Cherry Biotech, 4Dcell, Kyoto University and several others. Moreover, in the present trend, OOCs are promoted generally by the sales agreements with the end-users that include the association of both the parties in modifying the OOCs for accomplishing the requirements of end-users.
The microchips have the distinguishing characteristics of matching the human microenvironment in vitro with the most exciting areas of scientific research. This effective advantage of OOCs is made potential by incorporating the biology with the advanced engineering technologies. Moreover, with the effective applications and features, the market of organ-on-chip is spread across the globe which includes few major regions such as North America, Europe, Asia Pacific region and the rest of the world. Whereas, in 2016 the global market for OOCs was worth at USD 20 billion and by 2021, it is anticipated that this will grow at a CAGR of 70.0% to reach USD 284.0 million in the year 2021.
The technology of OOC is still at an initial stage of development, commercialization, and research. Whereas, the small structure of the market is major because of the fact that OOCs have not yet been fully commercialized. Moreover, the market is still in the research and development stage and is generally being used by a sufficient number of end-users. The OOC market is anticipated to grow with the positive CAGR due to a significant increase in the number of collaborative sales agreements. Therefore, in the coming years, it is expected that the global market of organ-on-chip will grow more effectively across the globe.
To Know More, Click On the link below:-
Ankur Gupta, Head Marketing & Communications